Kazia KZIA 深 滬
已收盤 02-06 16:00:00 美东时间
5.79
+0.170
+3.02%
華盛通- 最 高6.11
- 今 開5.94
- 成交量 10.24万股
- 最 低 5.705
- 昨 收 5.62
- 總市值 6563.54万
- 52周最高 17.40
- 市盈率 靜 --
- 換手率 0.90%
- 52周最低 2.90
- 委 比 83.45%
- 總股本 1133.60万
- 歷史最高 744.50
- 量 比 0.74
- 振 幅 7.21%
- 歷史最低 3.005
- 每 手 1
- 風險率 2.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Kazia Therapeutics Announces Three Patients With Metastatic Triple-Negative Breast Cancer With Paxalisib-Based Regimens Have Demonstrated Meaningful Clinical Responses In Phase 1b Trial Of Paxalisib In Combination With Pembrolizumab And Chemotherapy
Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV),
01-27 21:11
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 7, 2026 /PRNewswire/ -- The global cancer drugs market is surging toward $594.3 billion by 2...
01-07 23:32
Is the Market Bullish or Bearish on Kazia Therapeutics Ltd?
Kazia Therapeutics Ltd's (NYSE:KZIA) short interest as a percent of float has f...
2025-12-27 01:00
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" o...
2025-12-22 21:00
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
Kazia Therapeutics Says First Patient From TNBC Trial Demonstrated 76% Tumor Volume Shrinkage With Corresponding Reductions In CTC And Clusters
First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clustersReinvigoration of immune system + turning cold tumors hotPreliminary
2025-12-10 21:07
What's Going On With Cancer Firm Kazia Therapeutics
Kazia announced a private placement of $50 million in equity securities. Proceeds will fund clinical development and extend cash runway.
2025-12-03 01:21
Kazia Therapeutics Announces ~$50M PIPE, Selling Ordinary Shares And Pre-Funded Warrants At A Price Equivalent To $5.00 Per ADS, Each ADS Representing 500 Ordinary Shares, With Expected Net Proceeds Of ~$46.5M
Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited
2025-12-02 22:06
Market-Moving News for November 19th
LOW: 6% | Lowe's shares are trading higher despite mixed Q3 financial results. The company raised FY25 sales guidance. PLUG: -22% | Plug Power shares are trading lower after the company announced a $375
2025-11-19 20:21
